Dr. Angelo Scuotto | Vaccinology | Best Researcher Award
Dr. Angelo Scuotto is an accomplished biotechnology researcher and R&D leader with extensive expertise in vaccine development, nanotechnology-based delivery systems, and bioprocess management. He earned his Bachelor’s degree in Cell Biology and Physiology followed by a Master’s degree in Biology and Biotechnology with a specialization in genomics, cellular, and molecular engineering from the University of Lille, before completing his Ph.D. in Biotechnology–Bacteriology through a CIFRE thesis at the University of Lille in collaboration with Bifinove SAS, where he studied bifidobacterial metabolites and their potential in preventing type 1 diabetes, earning a nomination for the “Trophées Force Awards.” Professionally, Dr. Scuotto has progressed from R&D Engineer and Project Leader at Bifinove SAS, where he specialized in fermentation processes, metabolite characterization, and preclinical studies, to GMP Pre-industrialisation Project Manager at Vaxinano, overseeing vaccine scale-up and regulatory compliance. Currently, as R&D Director at Vaxinano, he manages vaccine and therapeutic pipelines, CDMO collaborations, GMP manufacturing, and strategic research directions. His research interests include immunotherapy, vaccine delivery innovations, parasitic diseases, and microbiota studies, supported by strong skills in qPCR, ELISA, fermentation optimization, molecular screening, and preclinical animal models. He has co-authored impactful publications on nanoparticle-based vaccines, immunotherapies, and novel delivery systems. Recognized for scientific excellence, including industry-linked awards and conference contributions, Dr. Scuotto continues to advance biotechnology innovation. In conclusion, his career reflects a dynamic blend of academic rigor, industrial translation, and leadership in global vaccine research.
Profile: Scopus
Featured Publications
Scuotto, A., Fasquelle, F., Betbeder, D., et al. (2025). Retrospective analysis of the impact of vaccination with an inactivated vaccine on toxoplasmosis-associated mortality in captive wildlife. Vaccines, 13(9), 910.
Ogonczyk-Makowska, D., Fasquelle, F., Vreulx, A. C., Scuotto, A., et al. (2024). Inactivated Toxoplasma gondii nanovaccine boosts T-cell memory response in a seropositive yellow-footed rock wallaby (Petrogale xanthopus) case report from Copenhagen Zoo. International Journal for Parasitology: Parasites & Wildlife.
Vergez, I., Nekoua, M. P., Rubrecht, C., Fasquelle, F., Scuotto, A., et al. (2024). Nanoparticles with a lipid core can enhance the infection of epithelial cells with an enterovirus. Intervirology, 67(1), 99-105.
Fasquelle, F., Scuotto, A., Howsam, M., Betbeder, D. (2024). Maltodextrin-Nanoparticles as a delivery system for nasal vaccines: A review article. Pharmaceutics, 16(2), 247.
Fasquelle, F., Scuotto, A., Vreulx, A. C., Petit, T., Charpentier, T., Betbeder, D. (2023). Nasal vaccination of six squirrel monkeys (Saimiri sciureus): Improved immunization protocol against Toxoplasma gondii with a nanoparticle-born vaccine. International Journal for Parasitology: Parasites & Wildlife, 22, 69-74.
Ramos, R. A. N., Giannelli, A., Fasquelle, F., Scuotto, A., Betbeder, D. (2023). Effective immunotherapeutic treatment of canine leishmaniasis. PLOS Neglected Tropical Diseases, 17(5), e0011360.